Adipocytokines in obesity and metabolic disease

Haiming Cao
National Heart, Lung and Blood Institute, National Institutes of Health, Center for Molecular Medicine, 10 Center Drive, Building 10, BN109, MSC 1760, Bethesda, Maryland 20892, USA

Abstract

The current global obesity pandemic is the leading cause for the soaring rates of metabolic diseases, especially diabetes, cardiovascular disease, hypertension, and non-alcoholic hepatosteatosis. Efforts devoted to find cures for obesity and associated disorders in the past two decades have prompted intensive interest in adipocyte biology, and have led to major advances in the mechanistic understanding of adipose tissue as an essential endocrine organ. Adipose tissue secretes an array of hormones (adipokines) that signal key organs to maintain metabolic homeostasis, and their dysfunction has been causally linked to a wide range of metabolic diseases. In addition, obesity induces production of inflammatory cytokines (often referred to together with adipokines as adipocytokines) and infiltration of immune cells into adipose tissue, which creates a state of chronic low-grade inflammation. Metabolic inflammation has been increasingly recognized as a unifying mechanism linking obesity to a broad spectrum of pathological conditions. This review focuses on classic examples of adipocytokines that have helped to form the basis of the endocrine and inflammatory roles of adipose tissue, and it also details a few newly characterized adipocytokines that provide fresh insights into adipose biology. Studies of adipocytokines in clinical settings and their therapeutic potential are also discussed.

Key Words

- adipocytokine
- obesity
- adipokine
- metabolic inflammation
- adipocyte

Introduction

In the past two decades, the world has seen a sustained increase in obesity, and the levels of overweight and obese persons worldwide have reached epidemic proportions (Finucane et al. 2011). It is well established that obesity induces all major metabolic disorders, especially diabetes, cardiovascular disease, hypertension, and fatty liver disease (Eckel et al. 2005). Mounting evidence also links obesity to a growing list of debilitating disorders including neurodegenerative disease, airway disorders, and cancer, all of which contribute to the staggering morbidity and mortality associated with obesity. Aimed at developing effective therapies for obesity and its associated disorders, scientists worldwide have intensified their efforts to elucidate the pathophysiological mechanisms by which obesity induces or amplifies its major adverse consequences. The concept of an adipocytokine was developed in this process and dysfunction of adipocytokine pathways has been recognized as a key etiological factor of obesity-induced disorders. Furthermore, the rational manipulation of adipocytokines is becoming a promising avenue of therapy for obesity and associated metabolic abnormalities.

Endocrine function of adipose tissue and adipokines

Obesity is the expansion of white adipose tissue (WAT), the most effective lipid storage organ in the body. In obese
subjects, white adipocytes in WAT have increased release of free fatty acids (FFAs) through lipolysis process leading to elevated serum fatty acid levels. This overflow of lipids from obese adipose depots has been considered a key reason for obesity-associated insulin resistance and hepatosteatosis for several decades (Randle et al. 1963, Samuel et al. 2010). But fatty acids in this setting have often been considered as a whole, and studies examining the distinct impact of individual lipid species have provided intriguing insights into the specificities of adipose-secreted lipids (Cao et al. 2008). In 1994, leptin was identified as an adipose-secreted hormone (adipokine) that exhibits potent anorexic effects, and this finding redefined WAT as an endocrine organ (Zhang et al. 1994). In the following two decades, several more adipokines were identified as critical regulators of systemic lipid and glucose homeostasis, and the list continues to grow (Fig. 1). Adipokines mediate the crosstalk between adipose tissue and other key metabolic organs, especially the liver, muscle, and pancreas, as well as the CNS (Rosen & Spiegelman 2006). Consistent with this notion, dysfunctions in adipokine pathways often result in impaired organ communications and metabolic abnormalities in multiple tissues thereby constituting a critical pathological component in the development of metabolic disease (Trujillo & Scherer 2006).

Metabolic inflammation and adipokines

Hotamisligil et al. (1993) showed that adipose tissue in obese mice secretes tumor necrosis factor α (TNFα), a proinflammatory cytokine typically produced by immune cells, and also demonstrated that adipocyte-derived TNFα plays a direct role in obesity-induced insulin resistance. This was the first functional link between obesity and inflammation, and over the years it has evolved into the concept of metabolic inflammation (Fig. 1), which has been widely accepted as an important mechanistic connection between obesity and its complications (Hotamisligil 2006). After TNFα, it was demonstrated that adipose tissue produces an array of cytokines and chemokines such as IL6 and MCP1, which either positively or negatively regulate systemic glucose and lipid metabolism. Interestingly some adipokines also exhibit features within adipose tissue and also travel to remote organs to regulate systemic energy metabolism. The level and action of adipokytokes are often altered in obese subjects, which contribute to obesity-induced disorders.
of cytokines or regulate inflammatory responses, and so these two groups of adipose-derived factors are often collectively referred to as ‘adipocytokines’ (Fig. 1). In 2003, two studies simultaneously reported that obesity induces macrophage infiltration of adipose tissue in both mice and humans (Weisberg et al. 2003, Xu et al. 2003b), which not only provided an explanation for the source of adipose-derived cytokines but also demonstrated for the first time the close juxtaposition between immune and metabolic cells in a metabolic organ. Adipose-resident macrophages are classified into two very distinct subtypes, M1, or classically activated, and M2, or alternatively activated. M1 macrophages secrete proinflammatory cytokines, such as TNFα and IL6, produce iNOS and reactive oxygen species (ROS), and cause insulin resistance. M2 macrophages produce IL10 and IL1 receptor antagonists and arginase-1 and have been implicated in tissue remodeling (Gordon 2003). Obesity causes a shift of macrophage subtypes in adipose tissue from M2 to M1 activation, leading to increased levels of proinflammatory cytokines and ROS, which induce insulin resistance (Lumeng et al. 2007). Meanwhile, the loss of certain beneficial effects associated with M2 macrophages might also contribute to the metabolic deterioration in obesity. For examples, M2 macrophages produce catecholamines that sustain adaptive thermogenesis (Nguyen et al. 2011), and lipolysis during fasting recruits macrophages that buffer local lipid increase and protect adipose function (Kosteli et al. 2010).

Following macrophages, nearly every major type of immune cell has been identified in adipose tissue in recent years (Feuerer et al. 2009, Liu et al. 2009, Winer et al. 2009, Wu et al. 2011) and is actively involved in the endocrine function of adipose tissue in systemic metabolic regulation. Furthermore, the close physical and signaling interactions between immune and metabolic cells also exist in all major metabolic organs of obese subjects especially the liver, muscle, and pancreas, indicating that metabolic inflammation is a universal feature and a pathological basis for obesity-induced metabolic dysfunction.

There are a number of potential underlying causes for obesity-induced adipose inflammation. Adipose tissue expansion in the development of obesity can cause hypoxia which induce compensatory angiogenesis. Macrophages are recruited to the site to facilitate the vascularization process (Pang et al. 2008). Similar function of immune cells was also demonstrated in other metabolic tissues such as liver where Kupffer cell-secreted TNFα and IL6 in mouse liver are required for efficient liver regeneration (Abshagen et al. 2007). Infiltrated macrophages in adipose tissues have also been proposed to be a mechanism to remove apoptotic cells (Cinti et al. 2005, Strissel et al. 2007). In addition, endotoxemia associated with altered gut permeability and obesity might potentiate adipose inflammation (Cani et al. 2007). Although accumulating evidence supports an overall negative effect of adipose inflammation on energy metabolism, it should bear in mind that not all metabolic inflammation is detrimental to metabolic homeostasis. Inflammation associated with adipose expansion or repair might be necessary for the body to adapt to the excess energy and maintain metabolic homeostasis (Ye & McGuinness 2013). In the same vein, certain cytokines stimulate energy expenditure and reduce food intake which might help to curtail obesity (Ye & Keller 2010). Therefore, the metabolic outcomes of adipose inflammation should always be considered in the context of their physiological underpinnings, and more studies are needed to fully understand the extent and mechanism of beneficial inflammatory responses associated with different stages of obesity.

Key adipocytokines in metabolic regulation and obesity-induced metabolic disorders

Leptin

Leptin was identified through positional cloning by Zhang et al. (1994), and is one of most potent adipocytokines in metabolic regulation. Leptin regulates body weight by signaling nutritional status to other organs especially the hypothalamus, which produces neuropeptides and neurotransmitters that modulate food intake and energy expenditure (Friedman & Halaas 1998). Leptin also has anti-diabetic effects independent of its regulation of body weight and energy intake (Kamohara et al. 1997). Leptin regulates hepatic lipogenesis by suppressing the expression of key enzymes in the fatty acid synthesis pathway (Cohen et al. 2002) and enhances muscle fatty acid oxidation by activating a critical energy sensor AMPK (Minokoshi et al. 2002).

At the signaling level, leptin activates the leptin receptor, which has multiple splicing isoforms, although the long isoform mediates all known leptin actions (Lee et al. 1996). There are multiple pathways downstream of the leptin receptor, each of which mediates different aspects of leptin activities (St-Pierre & Tremblay 2012). The main signaling branch of leptin is the JAK–STAT pathway, which regulates expression of anorexigen neuropeptides (Baumann et al. 1996). This pathway is essential...
Adiponectin

Several research groups identified adiponectin almost simultaneously as an abundantly secreted adipokine (Scherer et al. 1995, Hu et al. 1996, Maeda et al. 1996, Nakano et al. 1996). Recombinant adiponectin can enhance insulin action and partially reverse insulin resistance in obese mice (Berg et al. 2001, Yamauchi et al. 2001). Consistently, multiple groups have reported that adiponectin-deficient mice develop insulin resistance associated with high level of TNFα in adipose tissue and reduced responsiveness to PPARα (Maeda et al. 2002, Nawrocki et al. 2006), although an independently generated adiponectin knockout mouse line has no change in insulin sensitivity (Ma et al. 2002). Adiponectin has also been reported to have antiatherogenic effects (Funahashi et al. 1999, Ouchi et al. 1999). In addition, adiponectin exhibits cardioprotective activity in ischemic heart disease through AMPK and cyclooxygenase 2 pathways (Shibata et al. 2005).

Adiponectin signaling is mediated by two adiponectin receptors, adipoR1 and adipoR2 (Yamauchi et al. 2003). AdipoR1 is ubiquitously expressed whereas adipoR2 is enriched in the liver tissue. Knockout of adipoR1 and adipoR2 abrogates adiponectin binding and causes lipid accumulation, inflammation, and insulin resistance (Yamauchi et al. 2007). Activation of adipoR1 in the liver and muscle tissues increases AMPK activity, which mediate the insulin sensitizing effect of adiponectin and also enhances fatty acid oxidation (Yamauchi et al. 2002). The adipoR2 pathway in the liver increases PPARα and expression of its target genes, which also results in increased fatty acid oxidation (Yamauchi et al. 2007). Recently, it has been reported that a variety of downstream effects of the adiponectin receptor are mediated by ceramide activity associated with adipoR1 and adipoR2 (Holland et al. 2011). Adiponectin also has anti-inflammatory effects that contribute to its protective role against metabolic stress in obesity. Adiponectin suppresses TNFα production in obese mice (Xu et al. 2003a), and adiponectin-deficient mice have high levels of TNFα in adipose tissue (Maeda et al. 2002). Low levels of plasma adiponectin are associated with C-reactive protein in humans (Ouchi et al. 2003). Adiponectin enhances the clearance of apoptotic cells by facilitating their opsonization and uptake by macrophages (Takemura et al. 2007).

Some of the anti-atherogenic effects of adiponectin are also mediated by its role in the suppression of inflammatory responses. Adiponectin inhibits nuclear factor-κB (NFκB) activity and its downstream adhesion molecules.
leading to reduced monocyte adhesion to endothelial cells (Ouchi et al. 1999, Okamoto et al. 2002). In addition, adiponectin confers vascular-protective activities by suppressing the apoptosis of endothelial cell (Kobayashi et al. 2004).

Clinical observations support the idea that plasma adiponectin levels are associated with obesity-induced disorders, especially diabetes. Plasma adiponectin levels are decreased in type 2 diabetic patients, and higher adiponectin levels are associated with low risk of diabetes (Li et al. 2009). Adiponectin levels are also negatively associated with adiposity and fasting glucose (Ryo et al. 2004). A multi-ethnic meta-analysis of a large cohort also demonstrated that numerous genetic loci associated with adiponectin levels influence risk of insulin resistance and type 2 diabetes (Dastani et al. 2012). Currently, several strategies to boost adiponectin levels or adiponectin receptor activities are being explored for the treatment of obesity-induced inflammation and insulin resistance (Yamauchi & Kadowaki 2008).

**Tumor necrosis factor α**

TNFα was the first cytokine identified in the adipose tissue of obese mice, marking the start of the metabolic inflammation concept (Hotamisligil et al. 1993). The direct involvement of TNFα in obesity-induced insulin resistance was confirmed by observations that TNFα treatment interferes with insulin signaling and blocks insulin actions (Hotamisligil et al. 1994). Mice lacking the functions of TNFα or its receptors are protected from obesity-induced insulin resistance and hyperglycemia (Uysal et al. 1997, 1998). It was initially thought that adipose-derived TNFα was produced mainly by adipocytes, but the parallel trend of macrophage infiltration and TNFα expression in adipose tissue of obese mice suggests that a significant portion of the adipose TNFα pool might be derived from macrophages and other immune cells. Interesting, FFA strongly stimulates TNFα production in macrophages (Nguyen et al. 2005) and in turn, TNFα stimulates lipolysis to increase fatty acid release from adipocytes (Wang et al. 2008). This FFA-cytokine cycle suggests that metabolic inflammation, once started, can use this self-perpetuating mechanism to further its inhibitory effects on insulin signaling and energy metabolism. In addition, TNFα directly stimulates hepatic lipogenesis in vivo (Feingold & Grunfeld 1987), and adipose-derived TNFα is also a major mechanistic link between obesity and cancer (Park et al. 2010).

TNFα exerts its effects through two distinct receptors, p55 and p75, which further activate JNK1 and inhibit IkB kinase(IKK)/NFκB pathways (Baud & Karin 2001). JNK1 can directly inhibit insulin signaling by phosphorylating insulin receptor substrate 1 (IRS1) on serine residues (Aguirre et al. 2002) and can also potentiate fatty acid-induced cytokine production (Nguyen et al. 2005). Consistent with these observations, JNK1 knockout mice are protected from obesity and insulin resistance (Hirosumi et al. 2002). IKK can also directly inhibit IRS1 function through serine phosphorylation in a manner similar to JNK1 (Gao et al. 2002) and also activate NFκB to produce inflammatory cytokines both in metabolic organs and myeloid cells. It has been demonstrated that systemic or selective inhibition of IKK in either hepatocytes or myeloid cells improves glucose metabolism in mice (Yuan et al. 2001, Arkan et al. 2005, Cai et al. 2005). TNFα also induces the expression of cytokine signaling 3 (SOCS3) suppressor, which inhibits insulin signaling by increasing ubiquitin-mediated IRS1 and IRS2 degradation (Emanuelli et al. 2001, Rui et al. 2002). Recently, a report has demonstrated that TNFα increase leptin receptor expression, raising an interesting possibility that TNFα might enhance leptin action (Gan et al. 2012), although the physiological relevance of this connection needs to be confirmed in an in vivo setting.

Numerous studies in humans have demonstrated strong associations between circulating TNFα and insulin resistance (Hivert et al. 2008) or other obesity-associated metabolic complications (Berg & Scherer 2005). However, attempts to block TNFα function in patients have not yet produced consistent metabolic outcomes. For example, neutralization of TNFα with an engineered antibody did not improve insulin sensitivity in type 2 diabetes patients (Ofei et al. 1996), whereas blockade of TNFα in patients with rheumatoid arthritis or psoriasis indeed improved their insulin resistance (Gonzalez-Gay et al. 2006, Lo et al. 2007). Considering the wide spectrum of inflammatory cytokines that are elevated in obesity, targeting TNFα alone might not have sufficient efficacy to improve systemic metabolic responses and might need to be considered in the context of managing the overall metabolic inflammation.

**Resistin**

Resistin was initially identified in a screen for adipocyte genes that are suppressed by insulin-sensitizing drugs in rodents (Steppan et al. 2001). Depletion of circulating resistin by a neutralizing antibody improves insulin action.
in obese mice, suggesting that resistin is an adipokine linking obesity to insulin resistance (Steppan et al. 2001). Subsequently, it was shown that resistin knockout mice on a high-fat diet have improved glucose metabolism mainly due to reduced glucose production in the liver (Banerjee et al. 2004). Resistin also expresses the expressions of cytokines and adhesion molecules in murine vascular endothelial cells and contributes to atherosclerosis (Burnett et al. 2005). Resistin circulates in two distinct assembly states, which exhibit differential activities in metabolic regulation (Patel et al. 2004). However, the relevance of resistin to human disease is complicated by the fact that rodent resistin is produced in adipocytes and human resistin is produced mostly in macrophages. Human and rodent resistin only shares 59% identity at the amino acid level, which is relatively low compared with other hormones (Ghosh et al. 2003). But interestingly, human resistin, when expressed in mouse macrophages, also induces insulin resistance (Qatanani et al. 2009) suggesting that human and mouse resistin might have similar function despite their different sites of production.

In humans, experimental endotoxemia induced elevated resistin and produced an insulin-resistant state (Lehrke et al. 2004). Epidemiological studies have associated elevated circulating resistin with increased risk for type 2 diabetes, inflammatory markers, myocardial infarction, and atherosclerosis (Burnett et al. 2005, 2006, Reilly et al. 2005, Heidemann et al. 2008, Chen et al. 2009). These studies support the idea that resistin levels could serve as an informative marker for metabolic disease in humans, and it will be of great interest to determine the therapeutic potential of resistin inhibition in future studies.

IL6

IL6 is one of the major pro-inflammatory cytokines whose expression level increases in the adipose tissue of obese mice and patients, but its role in glucose metabolism has not been fully resolved. IL6 depletion in obese mice with a neutralizing antibody improves hepatic insulin action (Klover et al. 2005) while chronic infusion of IL6 causes insulin resistance in the liver of mice (Klover et al. 2003). Conversely, mice with targeted ablation of IL6 develop obesity and insulin resistance, which can be reversed by centrally delivered exogenous IL6 (Wallenius et al. 2002) suggesting that IL6 is required for the maintenance of whole-body glucose metabolism and metabolic homeostasis. An independently generated IL6-targeted mutation mouse line, however, does not develop obesity or insulin resistance and only exhibits elevated glucose level in a glucose tolerance test (Di Gregorio et al. 2004). In a mouse model with adipose-specific ablation of JNK1, increased secretion of IL6 was proposed to be the primary reason for systemic insulin resistance (Sabio et al. 2008). There are several potential explanations for the seemingly contradictory data regarding IL6 in insulin action and glucose metabolism. Effects of acute vs chronic treatments need to be differentiated and dose and site of action of IL6 need to be carefully considered. In addition, IL6 produced by different organs might also contribute to its complex effects on metabolic regulation.

During exercise, IL6 is mainly released from working skeletal muscle. IL6 release from contracting skeletal muscle might mediate the beneficial effects associated with exercise, including increased glucose uptake and fatty acid oxidation (Febbraio & Pedersen 2002). It appears that activation of AMPK by IL6 mediates these effects (Al-Khalili et al. 2006). In addition, transgenically expressed human IL6 in mice increases leptin sensitivity and prevents diet-induced obesity (Sadagurski et al. 2010). However, the function of muscle-derived IL6 might also vary depending on its context. In a mouse model with muscle-specific disruption of PPARα coactivator 1z (PGC1α), muscle-secreted IL6 causes impaired insulin production from pancreatic islets and glucose intolerance (Handschin et al. 2007).

In patient studies, increased serum IL6 correlates with obesity and insulin resistance (Vozarova et al. 2001, Bastard et al. 2002, Spranger et al. 2003). The IL6 174G>C single nucleotide polymorphism (SNP) is associated with insulin resistance and metabolic syndrome (Fernandez-Real et al. 2000, Stephens et al. 2007). However, the mechanism of action of IL6 in human metabolism needs to be further studied to understand the therapeutic potential of IL6, partly due to the fact that there is low similarity between human and mouse IL6, and thus information generated from mouse studies cannot be readily applied to humans. To add to the complexity of IL6 signaling in human metabolism, two reports showed that MAB against the IL6 receptor, Tocilizumab, either increases or has no effects on insulin sensitivity in patients with rheumatoid arthritis (Schultz et al. 2010, Ogata et al. 2011, Ye & McGuinness 2013).

Rbp4

Rbp4 is a transport protein for retinol in systemic circulation, and is mainly produced by the liver but also expressed in white adipocytes. Rbp4 was first characterized as an adipokine based on the finding that Rbp4 is highly
secreted from adipose tissue of Glut4-deficient mice and contributes to insulin resistance in this mouse model (Yang et al. 2005). In humans, higher Rbp4 levels are also associated with insulin resistance in obese and diabetic subjects (Graham et al. 2006). In addition, a number of Rbp4 SNPs have been identified and several of them are associated with increased risk for type 2 diabetes (Kovacs et al. 2007, Munkhtulga et al. 2007). However, several reports failed to detect the association of Rbp4 with insulin resistance (von Eynatten et al. 2007, Promintzer et al. 2007, Yao-Borengasser et al. 2007), potentially due to shortcomings in the methodologies for quantifying Rbp4 levels (Kotnik et al. 2011). In general, clinical studies on children and adolescents have been more consistent in supporting a role for Rbp4 in obesity and insulin resistance, suggesting that Rbp4 might be more involved in the early stages of metabolic syndrome (Kotnik et al. 2011).

**Secreted frizzled-related protein 5**

Secreted frizzled-related protein 5 (Sfrp5) was recently identified as an anti-inflammatory adipocytokine (Ouchi et al. 2010). Sfrp5 is highly expressed in adipose tissue of lean mice but downregulated in obese mice. Targeted mutation of Sfrp5 in mice caused insulin resistance, glucose intolerance, and hepatosteatosis when the animals were fed a high-fat diet (Ouchi et al. 2010). Mechanistically, Sfrp5 activates JNK1 through noncanonical Wnt signaling to increase the levels of inflammatory cytokines and block insulin action (Ouchi et al. 2010). However, a second independently generated Sfrp5 mutation mouse line was reported to have different phenotypes, and accordingly the authors proposed a very different mechanism of actions for Sfrp5. In this study, Sfrp5-deficient mice were resistant to diet-induced obesity due to enhanced mitochondrial activities (Mori et al. 2012). Sfrp5 deficiency increased the expression of PGC1 and mitochondrial transcription factor A (Tfam), leading to increased mitochondrial biogenesis. Lack of Sfrp5 also stimulated mitochondrial respiration and gene expression through Wnt3a activity (Mori et al. 2012). The cause of these discrepancies is unclear. Human studies regarding Sfrp5 in metabolic disease have also given rise to conflicting data (Carstensen et al. 2013, Hu et al. 2013). Regardless, further studies about the function of Sfrp5 in metabolic regulation could provide important insights into adipose biology. Sfrp5 regulates multiple Wnt proteins that play a crucial role in adipogenesis (Cristancho & Lazar 2011). Dissecting the Sfrp5/Wnt network in adipose tissue could also help to explain the autocrine/paracrine mechanism of metabolic inflammation, which is still poorly understood.

**aP2, a lipid-activated adipocytokine**

The identification of aP2 as a lipid-activated adipokine is a surprising and exciting finding considering it has been extensively studied for over two decades as an essential intracellular regulator of lipid metabolism and inflammation in metabolic disease. AP2 is a member of fatty acid-binding protein (FABP) family and was initially thought to be exclusively expressed in adipocytes. In fact, the aP2 promoter has been widely used to specially drive transgene expression in adipose tissue. AP2-deficient mice have normal adiposity and gain more weight than controls when fed with high-fat diet, but they were partially protected from obesity-induced insulin resistance (Hotamisligil et al. 1996). The mild effect of aP2 deficiency could be due to the upregulation of mal1, a related FABP (Maeda et al. 2005). Therefore, mice deficient in both FABPs were produced to study the full impact of adipose FABP deficiency. The double-knockout mice have reduced adiposity, enhanced insulin sensitivity, and reduced hepatosteatosis (Maeda et al. 2005). It appears that some of the beneficial effects of FABP deficiency are mediated by robust upregulation of the fatty acid species, palmitoleate (C16:1n7), in the adipose tissue and its secretion into circulation (Fig. 2). Palmitoleate enhances insulin action in the muscle and suppresses de novo lipogenesis in the liver (Cao et al. 2008).

Yet the molecular mechanism for the pronounced reduction in gluconeogenesis in FABP-deficient mice remained elusive until it was found that aP2 is in fact actively secreted from adipocytes to control liver glucose metabolism (Cao et al. 2013; Fig. 2). Secretion of aP2 from adipocytes is regulated by lipolysis, which might be the reason that circulating aP2 levels are markedly elevated in obesity. Recombinant aP2 stimulates hepatic glucose production whereas neutralization of secreted aP2 reduces glucose production and corrects the diabetic phenotype of obese mice (Cao et al. 2013).

aP2 is the first adipokine whose secretion is strongly regulated by lipolysis-released fatty acids, suggesting that aP2 might function as a lipid sensor in adipocytes and might also carry specific lipids in plasma to specific organs or cells. Therefore, like other well-studied adipocytokines, it is conceivable that secreted aP2 could potentially act on other key organs such as the CNS or heart to regulate other aspects of metabolic homeostasis (Fig. 2) and these
questions need to be addressed in future studies. Another interesting question is whether secreted aP2 is also involved in metabolic inflammation. Despite long having been considered an adipocyte-specific protein, aP2 was found to be expressed in the macrophages (Makowski et al. 2001) and can be quickly induced by endotoxin (Kazemi et al. 2005). Mice with aP2 deficiency in macrophages are protected from atherosclerosis partly because of activated PPARγ and reduced inflammatory responses (Makowski et al. 2005). The proinflammatory action of aP2 was also demonstrated in an asthma mouse model, in which aP2 deficiency protects mice from airway inflammation (Shum et al. 2006). It will be interesting to investigate whether aP2 is also secreted from macrophages and whether secreted aP2 regulates inflammatory responses in metabolic diseases (Fig. 2).

Accumulating evidence suggests that circulating aP2 is implicated in human metabolic syndrome. Plasma aP2 levels are closely associated with obesity and metabolic syndrome in cohorts of multiple ethnicities (Stejskal & Karpisek 2006, Xu et al. 2006, Simon et al. 2009). In addition, circulating aP2 has also been linked to carotid atherosclerosis in humans (Yeung et al. 2007) and non-alcoholic fatty liver disease (NAFLD; Koh et al. 2009). In NAFLD patients, elevated plasma aP2 levels independently predict inflammation and fibrosis (Milner et al. 2009). Neutralizing secreted aP2 robustly improves glucose metabolism (Cao et al. 2013), indicating that plasma aP2 could constitute a potential therapeutic target for diabetes, NAFLD, and cardiovascular disease.

**Conclusion and future perspective**

There is overwhelming evidence that adipocytokines play a pivotal role in metabolic homeostasis of healthy subjects, and that deficiencies in these factors, caused by excess adiposity and adipocyte dysfunction, are a central component in the pathogenesis of the constellation of diseases surrounding obesity. Therefore, it will be fruitful to fully define the secretome of adipose tissue; novel adipocytokines identified in this process will, no doubt, provide critical insights into the functions of adipose tissue as an essential metabolic regulator. Identifying receptors for existing adipocytokines and mapping their downstream signaling pathways, especially in the context of metabolic disorders, is another area of research that could generate fresh therapeutic targets for managing adipocytokines to treat metabolic diseases. Due to the intertwined nature of metabolic and immune cells in major metabolic organs, further mechanistic
investigations are required to understand how adipocytokines integrate metabolic and inflammatory responses in each site and the pathological significance of these responses in metabolic disorders. It is particularly important to differentiate the detrimental effects of metabolic inflammation inflicted by nutritional stress and those beneficial ones underlying the physiological tissue response when designing anti-inflammation therapies for metabolic disorders (Ye & McGuinness 2013). Following the example of adipocytokines, numerous muscle- and hepatocyte-secreted hormones (myokine and hepatokine) have been identified as essential metabolic regulators. Therefore, it is very likely that a comprehensive endocrine network of organ communications in nutrient sensing and metabolic homeostasis could be established in the foreseeable future. Such a blueprint of organ crosstalk would have far-reaching impact on the development of effective therapies against obesity and metabolic disease.

Declaration of interest
The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding
H C is funded by the Division of Intramural Research of the National Heart, Lung and Blood Institute (HL006103-02) of the NIH, USA. The author expresses his apology for not being able to cite all worthy papers owing to space limitation.

References
Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J & Hainque B 2002 Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vitro and in vivo. Journal of Clinical Endocrinology and Metabolism 87 2084–2089. (doi:10.1210/jc.87.5.2084)


Hotamisligil GS, Murray DL, Choy LN & Spiegelman BM 1994 Tumor necrosis factor-α inhibits signaling from the insulin receptor. PNAS 91 4854–4858. (doi:10.1073/pnas.91.11.4854)


Kazemi MR, McDonald CM, Shigenaga JK, Grunfield C & Feingold KR 2005 Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arteriosclerosis, Thrombosis, and Vascular Biology 25 1220–1224. (doi:10.1161/01.ATV.000019163.52632.1b)


Kazemi MR, McDonald CM, Shigenaga JK, Grunfield C & Feingold KR 2005 Adipocyte fatty acid-binding protein expression and lipid accumulation are increased during activation of murine macrophages by toll-like receptor agonists. Arteriosclerosis, Thrombosis, and Vascular Biology 25 1220–1224. (doi:10.1161/01.ATV.000019163.52632.1b)


macrophages produce catecholamines to sustain adaptive thermo-
Ofei F, Hurel S, Newkirk J, Sopwith M & Taylor R 1996 Effects of an
engineered human anti-TNF-α antibody (CDP571) on insulin
sensitivity and glycemic control in patients with NIDDM. Diabetes
45 881–885. (doi:10.2337/db45.7.881)
Ogata A, Morishima A, Hirano T, Hishitani Y, Hagihara K, Shima Y, Narazaki M &
Tanaka T 2011 Improvement of HbA1c during treatment with humanised
anti-interleukin 6 receptor antibody, tocilizumab. Annals of
Rheumatic Disease 70 1164–1165. (doi:10.1136/ard.2010.132845)
atherosclerosis in apolipoprotein E-deficient mice. Circulation 106
2767–2770. (doi:10.1161/01.CIR.0000042707.50032.19)
adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 2473–2476. (doi:10.1161/01.CIR.100.25.2473)
association of C-reactive protein with adiponectin in blood stream and
(doi:10.1126/science.1188280)
Pang C, Gao Z, Yin J, Zhang J, Jia W & Ye J 2008 Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue
remodeling in obesity. American Journal of Physiology. Endocrinology
and Metabolism 295 E113–E322. (doi:10.1152/ajpendo.90296.2008)
Karin M 2010 Dietary and genetic obesity promote liver inflammation and insulin resistance in mice. Journal of Clinical Investigation
115 1540–1552. (doi:10.1172/JCI37272)
Journal of Clinical Investigation 122 1725–1734. (doi:10.1172/JCI55283)
Perlman JM, Cargile K, Akinc SA, Arendt RE, Hovey RM et al. 2014 Human adipose tissue serves as an endocrine organ to control energy
nature05483)
Rui L, Yuan M, Frantz D, Shoelson S & White MF 2002 SOCS-1 and SOCS-3
block insulin signaling by ubiquitin-mediated degradation of IRS1 and
IRS2. Journal of Biological Chemistry 277 42394–42398. (doi:10.1074/
jc20044200)
Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y & Funahashi T 2004 Adiponectin as a biomarker of the
circj.68.975)
2008 A stress signaling pathway in adipose tissue regulates hepatic insulin
Sadagurski M, Norquay L, Farhang J, D’Aquino K, Coppis K & White MF
2010 Human IL6 enhances leptin action in mice. Diabetologia 53
525–535. (doi:10.1007/s00125-009-1580-8)
(doi:10.1016/S0140-6736(10)60408-4)
serum protein similar to C1q, produced exclusively in adipocytes. Journal of
Biological Chemistry 270 26746–26749. (doi:10.1074/jbc.270.
25.26746)
Schulz O, Oberhauser F, Sach J, Rubbert-Roth A, Hahn M, Krone W &
Laufs M 2010 Effects of inhibition of interleukin-6 signalling on insulin
sensitivity and lipoprotein (a) levels in human subjects with
0014328)
Shibata R, Sato K, Pimentel DR, Takemura Y, Kihara S, Ohashi K, Funahashi T,
Ouchi N & Walsh K 2005 Adiponectin protects against myocardial ischemia–reperfusion injury through AMPK- and COX-2-dependent
Shum BO, Mackay CR, Gorgun CZ, Frost MJ, Kumar RK, Hotamisligil GS &
Rolph MS 2006 The adipocyte fatty acid-binding protein aP2 is essential in
allergic airway inflammation. Journal of Clinical Investigation 116
2183–2192. (doi:10.1172/JC24767)
Simon I, Escote X, Villarrasa N, Gomez J, Fernandez-Real JM, Megia A,
Gutierrez C, Gallart I, Masdeval C & Vendrell J 2009 Adipocyte fatty
acid-binding protein as a determinant of insulin sensitivity in morbidly
obese women. Obesity 17 1124–1128.
Spranger J, Kroe A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M,
Boeing H & Pfeiffer AF 2003 Inflammatory cytokines and the risk to
develop type 2 diabetes: results of the prospective population-based
European Prospective Investigation into Cancer and Nutrition (EPIC)–
Potsdam Study. Diabetes 52 812–817. (doi:10.2337/diabetes.52.3.812)
Stejskal D & Karpisek M 2006 Adipocyte fatty acid binding protein in a
Caucasian population: a new marker of metabolic syndrome? European
2006.01696.x)
Association between plasma IL-6, the IL6 -174G>C gene variant and the
metabolic syndrome in type 2 diabetes mellitus. Molecular Genetics
and Metabolism 90 422–428. (doi:10.1016/j.ymgme.2006.10.004)
Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR,
Ahima RS & Lazar MA 2001 The hormone resistin links obesity to diabetes.
Nature 409 307–312. (doi:10.1038/35033000)
St-Pierre J & Tremblay ML 2012 Modulation of leptin resistance by protein
cmet.2012.02.004)
Strissel KJ, Stancheva Z, Miyoshi H, Perfield JW II, DeFuria J, Jick Z,
Greenberg AS & Obin MS 2007 Adipocyte death, adipose tissue
remodeling, and obesity complications. Diabetes 56 2910–2918.
(doi:10.2337/db07-0767)
Takemura Y, Ouchi N, Shibata R, Arahanian T, Kirber MT, Summer RS,
Kihara S & Walsh K 2007 Adiponectin modulates inflammatory
reactions via calreticulin receptor-dependent clearance of early
(printed 23 April 2007)


Received in final form 30 October 2013

Accepted 7 November 2013